Myriad Genetics: Paul Bisaro

Myriad Genetics elected Paul M. Bisaro to its Board of Directors, effective immediately. Bisaro previously served as executive chairman of Amneal Pharmaceuticals and as president and CEO of Impax Laboratories, prior to its acquisition by Amneal. In addition to his new board position with Myriad, Bisaro currently serves as a director on the boards of Zoetis, TherapeuticsMD, and Mallinckrodt.